This Pilot study evaluates the use of a new device called Inflammacheck and whether it can consistently measure hydrogen peroxide levels in exhaled breath condensate. It will also assess whether exhaled breath condensate hydrogen peroxide levels as measured by Inflammacheck can differentiate people with asthma and COPD from healthy individuals.
Hydrogen Peroxide levels in Exhaled Breath Condensate (EBC) is a direct biomarker of oxidative stress from the airway epithelium. Levels have been shown to be raised in asthma and Chronic Obstructive Pulmonary Disease (COPD) both in stable and exacerbating states. Previously it has been difficult to measure this volatile compound away from a laboratory based setting. However a new device has been developed to measure Hydrogen peroxide levels in exhaled breath by the patients side. This Pilot study will test this new device in a clinical setting. It will assess whether the device can monitor levels consistently and reliably and whether it can distinguish disease from healthy individuals.
Study Type
OBSERVATIONAL
Enrollment
149
A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
Portsmouth Hospitals NHS Trust
Portsmouth, United Kingdom
Exhaled Breath Condensate hydrogen peroxide levels as measured by the inflammacheck device.
Time frame: 12 months
Disease severity as measured by Global Initiative for Asthma (GINA) Stage for asthma.
Time frame: 12 months
Disease severity as measured by Global Obstructive Lung Disease (GOLD) Stage for COPD.
Time frame: 12 months
Disease control as measured by the Asthma Control Questionnaire (ACQ) score for asthma patients.
Time frame: 12 months
Disease control as measured by the COPD Assessment Test (CAT) score for COPD patients.
Time frame: 12 months
Quality of life as measured by the Asthma Quality of Life Questionnaire (AQLQ) score in asthma patients
Time frame: 12 months
Lung function as recorded by the forced expiratory volume in 1 second (FEV1)
Time frame: 12 months
Eosinophilic Lung Inflammation as recorded by the exhaled Nitric Oxide level (FeNO).
Time frame: 12 months
Usability of inflammacheck device as measured by how frequently patients are unable to perform EBC collection by using the 'Inflammacheck' device.
Time frame: 6 months
Acceptability of the inflammacheck device as measured by a questionnaire of the participants and healthcare professionals experience of 'Inflammacheck'.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 6 months